$Meiragtx Holdings Plc(MGTX)$

MGTX has great potential with its breakthrough technologies in Gene Therapies, especially for treatment of Inherited Retina Diseases (IRD). Singapore National Eye Centre (SNEC) has shown great interest in Gene therapies with its relatively recent set up of department of IRD within SNEC itself. The latest UK regulatory approval of one of MGTX solutions is yet another indication of MGTX great potential for upside in its price. No wonder that current postmarket price hits $6.75 #MGTX

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Boon118
2025-07-01
Boon118
MGTX目前正在研究的遗传性视网膜疾病是X连锁视网膜色素变性（XLRP），MGTX已经完成了3期研究。除了MGTX的这种乐观的XLRP基因疗法之外，没有其他已知的RP治疗方法
Boon118
2025-07-01
Boon118
Amendment: I meant the latest UK regulatory approval for transaction with Hologen

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":451792155844832,"tweetId":"451792155844832","gmtCreate":1751326614895,"gmtModify":1751326618032,"author":{"id":4087984901983600,"idStr":"4087984901983600","authorId":4087984901983600,"authorIdStr":"4087984901983600","name":"Boon118","avatar":"https://community-static.tradeup.com/news/f89a32f4af0ad39abf173fbc3e26a060","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/MGTX\">$Meiragtx Holdings Plc(MGTX)$ </a>&nbsp;\nMGTX has great potential with its breakthrough&nbsp;technologies in Gene Therapies, especially&nbsp;for treatment of Inherited Retina Diseases (IRD). Singapore National Eye Centre (SNEC) has shown great interest in Gene therapies with its relatively&nbsp;recent set up of department of IRD within SNEC itself. The latest UK regulatory&nbsp;approval of one of MGTX solutions is yet another indication of MGTX great potential for upside in its price. No wonder that current postmarket price hits $6.75 #MGTX</body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/MGTX\">$Meiragtx Holdings Plc(MGTX)$ </a>&nbsp;\nMGTX has great potential with its breakthrough&nbsp;technologies in Gene Therapies, especially&nbsp;for treatment of Inherited Retina Diseases (IRD). Singapore National Eye Centre (SNEC) has shown great interest in Gene therapies with its relatively&nbsp;recent set up of department of IRD within SNEC itself. The latest UK regulatory&nbsp;approval of one of MGTX solutions is yet another indication of MGTX great potential for upside in its price. No wonder that current postmarket price hits $6.75 #MGTX</body></html>","text":"$Meiragtx Holdings Plc(MGTX)$ MGTX has great potential with its breakthrough technologies in Gene Therapies, especially for treatment of Inherited Retina Diseases (IRD). Singapore National Eye Centre (SNEC) has shown great interest in Gene therapies with its relatively recent set up of department of IRD within SNEC itself. The latest UK regulatory approval of one of MGTX solutions is yet another indication of MGTX great potential for upside in its price. No wonder that current postmarket price hits $6.75 #MGTX","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/451792155844832","repostId":0,"isVote":1,"tweetType":1,"viewCount":1877,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["MGTX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":437,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":451712657575992,"commentId":"451712657575992","gmtCreate":1751327742795,"gmtModify":1751327748063,"authorId":4087984901983600,"author":{"id":4087984901983600,"idStr":"4087984901983600","authorId":4087984901983600,"name":"Boon118","avatar":"https://community-static.tradeup.com/news/f89a32f4af0ad39abf173fbc3e26a060","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":451792155844832,"objectIdStr":"451792155844832","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"MGTX目前正在研究的遗传性视网膜疾病是X连锁视网膜色素变性（XLRP），MGTX已经完成了3期研究。除了MGTX的这种乐观的XLRP基因疗法之外，没有其他已知的RP治疗方法","text":"MGTX目前正在研究的遗传性视网膜疾病是X连锁视网膜色素变性（XLRP），MGTX已经完成了3期研究。除了MGTX的这种乐观的XLRP基因疗法之外，没有其他已知的RP治疗方法","html":"MGTX目前正在研究的遗传性视网膜疾病是X连锁视网膜色素变性（XLRP），MGTX已经完成了3期研究。除了MGTX的这种乐观的XLRP基因疗法之外，没有其他已知的RP治疗方法","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"hot","coins":0,"score":0,"disclaimerType":0},{"id":451707661131944,"commentId":"451707661131944","gmtCreate":1751326968374,"gmtModify":1751326973371,"authorId":4087984901983600,"author":{"id":4087984901983600,"idStr":"4087984901983600","authorId":4087984901983600,"name":"Boon118","avatar":"https://community-static.tradeup.com/news/f89a32f4af0ad39abf173fbc3e26a060","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":451792155844832,"objectIdStr":"451792155844832","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Amendment: I meant the latest UK regulatory approval for transaction with Hologen","text":"Amendment: I meant the latest UK regulatory approval for transaction with Hologen","html":"Amendment: I meant the latest UK regulatory approval for transaction with Hologen","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/451792155844832"}